ILY Robotic System vs Manual Flexible Ureteroscopy for Kidney Stone Treatment
Launched by ALBERT EL HAJJ · May 21, 2025
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two different methods for treating kidney stones: a robotic system called the ILY® robot and a manual technique known as flexible ureteroscopy. The main goals are to see if the robotic approach works just as well as the manual one, if it is just as safe or even safer, and if it makes the procedure easier for the surgeon. Participants will be randomly assigned to receive either treatment and will be monitored to check if the stones are successfully removed and if they experience any complications in the weeks following the procedure.
To be eligible for this trial, you need to be at least 18 years old and have a confirmed diagnosis of kidney stones. You should also have a normal kidney structure and be able to give informed consent. If you join the study, you’ll undergo standard evaluations before and after the procedure, including a CT scan to see if the stones are gone 30 days later. The trial is currently recruiting participants, and it’s open to both men and women. If you have any questions or think you might qualify, it’s a good idea to talk to your doctor for more information.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Males or females ≥ 18 years old
- • Patients with a normal pelvicalyceal anatomy
- • Patients with renal stone diagnosis confirmed by noncontrast computed tomography regardless of stone size, location, and multiplicity
- • ASA score I-III
- • Intact mental and cognitive ability to provide informed consent and willingness to participate in the study with 30-day follow-up
- Exclusion Criteria:
- • Children \< 18 and pregnant women
- • Patients with anatomically anomalous kidneys, known case of stricture or stenosis, or recent 3-month history of ureteroscopy (DJ stent placement only will be accepted) or known history of complicated ureteroscopy
- • Patients in whom stone measurement was not feasible on NCCT or those with concomitant ureteric stones.
- • ASA score IV
- • Mentally incapacitated patients unable to provide informed consent
About Albert El Hajj
Albert El Hajj is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative clinical studies. With a focus on precision and integrity, the organization collaborates with leading healthcare professionals and institutions to develop and evaluate new therapies across various therapeutic areas. Albert El Hajj emphasizes adherence to regulatory standards and ethical practices, ensuring that all trials are conducted with the utmost care for participant safety and scientific rigor. Through its comprehensive approach and commitment to excellence, the organization aims to contribute significantly to the field of medicine and enhance the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beirut, , Lebanon
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported